Key facts
- This page summarizes Richard L. Gelfond's Form 4 filing for IMAX CORP (IMAX).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2026, 17:37.
Richard L. Gelfond - 18 Aug 2026 Form 4 Insider Report for IMAX CORP (IMAX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- IMAX
- Reported as of
- 18 Aug 2026
- Net transaction value
- -$23,984,308
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2026, 17:37:45 UTC
- Prior SEC filing
- 28 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard L. Gelfond
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Richard L. Gelfond filed Form 4 for IMAX CORP (IMAX) on 20 Aug 2026.
Change
- Previous filing in this sequence was filed on 28 Apr 2026.
- Current net transaction value: -$23,984,308.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0000944011
Primary reporting owner
GELFOND RICHARD L
- Relationship
- Chief Executive Officer, Director
- Address
- 902 BROADWAY, 20TH FLOOR, NEW YORK
- Signature
- /s/ Richard L. Gelfond
- Signature date
- 20 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMAX
transaction
common shares
Conversion of derivative security
- Transaction value
- Shares
- +151,253
- Change %
- +20%
- Price
- $31.90*
- Shares after
- 916,255
- Date
- 18 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
IMAX
transaction
common shares
Sale
- Transaction value
- $7,714,644
- Shares
- -151,253
- Change %
- -17%
- Price
- $51.00
- Shares after
- 765,002
- Date
- 18 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
IMAX
transaction
common shares
Conversion of derivative security
- Transaction value
- Shares
- +205,504
- Change %
- +27%
- Price
- $31.90*
- Shares after
- 970,506
- Date
- 19 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
IMAX
transaction
common shares
Sale
- Transaction value
- $10,946,294
- Shares
- -205,504
- Change %
- -21%
- Price
- $53.27
- Shares after
- 765,002
- Date
- 19 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
IMAX
transaction
common shares
Sale
- Transaction value
- $5,323,370
- Shares
- -100,000
- Change %
- -13%
- Price
- $53.23
- Shares after
- 665,002
- Date
- 20 Aug 2026
- Ownership
- Direct
IMAX
holding
common shares (opening balance)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 765,002
- Date
- 18 Aug 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMAX
transaction
Derivative
stock options (to buy)
Conversion of derivative security
- Transaction value
- Shares
- -151,253
- Change %
- -11%
- Price
- $31.90*
- Shares after
- 1,181,158
- Date
- 18 Aug 2026
- Ownership
- Direct
- Underlying class
- common shares
- Underlying amount
- 151,253
- Exercise price
- $31.90
- Footnotes
- F3, F4, F5
IMAX
transaction
Derivative
stock options (to buy)
Conversion of derivative security
- Transaction value
- Shares
- -205,504
- Change %
- -17%
- Price
- $31.90*
- Shares after
- 975,654
- Date
- 19 Aug 2026
- Ownership
- Direct
- Underlying class
- common shares
- Underlying amount
- 205,504
- Exercise price
- $31.90
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
Represents the conversion upon exercise of stock options into common shares pursuant to a 10b5-1 Plan dated May 19, 2026.
Footnote F2
Represents the sale of converted common shares pursuant to a 10b5-1 Plan dated May 19, 2026.
Footnote F3
These options were issued in 2017 and are set to expire on January 3, 2027.
Footnote F4
The stock options became exercisable in nine installments: 39,640 on each of May 1, 2017, September 1, 2017, May 1, 2018, December 31, 2018, September 1, 2019 and December 31, 2019, and 39,639 on each of December 31, 2017, September 1, 2018 and May 1, 2019.
Footnote F5
This represents the number of common shares for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 975,654, 231,562 and 665,002, respectively.